Andrzej Januszewicz Selected Research

Sodium

4/2023	Impact of public restrictive measures on hypertension during the COVID-19 pandemic: existing evidence and long-term implications.
1/2021	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension.
12/2014	Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.
1/2011	Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrzej Januszewicz Research Topics

Disease

41	Hypertension (High Blood Pressure) 05/2024 - 01/2005
24	Paraganglioma (Paragangliomas) 01/2022 - 01/2004
16	Pheochromocytoma 01/2022 - 05/2002
14	Neoplasms (Cancer) 01/2022 - 08/2006
7	Hyperaldosteronism (Conn Syndrome) 03/2024 - 01/2013
5	Heart Failure 01/2023 - 01/2013
4	Essential Hypertension 01/2020 - 01/2003
4	Renal Artery Obstruction (Renal Artery Stenosis) 01/2016 - 06/2003
4	Type 2 Diabetes Mellitus (MODY) 12/2014 - 02/2006
3	Albuminuria 02/2024 - 02/2006
3	Chronic Renal Insufficiency 01/2023 - 01/2013
3	Pathologic Constriction (Stenosis) 01/2021 - 12/2017
3	Obstructive Sleep Apnea 01/2021 - 10/2011
3	Adenoma (Adenomas) 01/2020 - 01/2013
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2017 - 06/2003
3	Multiple Endocrine Neoplasia Type 2a (MEN 2) 05/2014 - 05/2002
2	Hypertensive Crisis 04/2024 - 11/2011
2	Malignant Hypertension 04/2024 - 01/2016
2	COVID-19 01/2024 - 11/2022
2	Body Weight (Weight, Body) 04/2023 - 01/2019
2	Hemorrhage 01/2023 - 01/2016
2	Obesity 01/2022 - 01/2019
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 06/2003
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 06/2014
2	Isolated Systolic Hypertension 12/2016 - 01/2011
2	Renal Insufficiency (Renal Failure) 01/2016 - 01/2012
2	Glucose Intolerance 01/2013 - 10/2011
2	Sleep Apnea Syndromes (Sleep Apnea) 01/2013 - 10/2011
2	von Hippel-Lindau Disease (von Hippel Lindau Disease) 01/2010 - 05/2002
1	Disease Progression 04/2024
1	Diabetes Mellitus 01/2024
1	Pulmonary Embolism 01/2023
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2022
1	Multiple Myeloma 01/2021
1	Amyloidosis 01/2021
1	Hypertrophy 12/2020
1	Atrial Fibrillation 09/2020
1	Vascular Remodeling 01/2020

Drug/Important Bio-Agent (IBA)

17	Antihypertensive Agents (Antihypertensives)IBA 05/2024 - 01/2003
15	CatecholaminesIBA 01/2022 - 12/2006
9	Succinate Dehydrogenase (Fumarate Reductase)IBA 01/2021 - 05/2002
8	NormetanephrineIBA 01/2022 - 03/2013
8	MetanephrineIBA 12/2020 - 03/2013
5	AldosteroneIBA 03/2024 - 11/2004
5	Angiotensin Receptor AntagonistsIBA 11/2022 - 02/2006
5	3-methoxytyramine (methoxytyramine)IBA 01/2022 - 01/2014
5	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 10/2011
4	SteroidsIBA 01/2024 - 05/2014
4	SodiumIBA 04/2023 - 01/2011
4	Hormones (Hormone)IBA 01/2019 - 08/2006
3	ReninIBA 03/2024 - 01/2014
3	DiureticsIBA 03/2024 - 12/2016
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2022 - 01/2017
3	Adrenergic Agents (Adrenergic Drugs)IBA 01/2022 - 04/2017
3	Mineralocorticoid Receptor AntagonistsIBA 10/2020 - 01/2015
3	Dopamine (Intropin)FDA LinkGeneric 08/2017 - 03/2013
2	mahuang-tangIBA 04/2024 - 01/2016
2	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 03/2024 - 11/2022
2	finerenoneIBA 02/2024 - 01/2021
2	Spironolactone (Aldactone)FDA LinkGeneric 02/2024 - 01/2021
2	Drug CombinationsIBA 01/2024 - 01/2017
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2023 - 01/2017
2	EnzymesIBA 01/2021 - 09/2016
2	Retinaldehyde (Retinal)IBA 01/2020 - 01/2016
2	CalciumIBA 01/2017 - 01/2013
2	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 01/2016 - 01/2007
2	Cystatin CIBA 02/2015 - 01/2010
2	AngiotensinsIBA 01/2014 - 11/2012
2	olmesartanIBA 04/2012 - 03/2011
2	DNA (Deoxyribonucleic Acid)IBA 01/2010 - 01/2010
2	Olmesartan Medoxomil (Votum)FDA Link 02/2006 - 01/2003
1	Immunosuppressive Agents (Immunosuppressants)IBA 04/2024
1	Chlorthalidone (Chlortalidone)FDA LinkGeneric 02/2024
1	ThiazidesIBA 11/2022
1	C-Reactive ProteinIBA 11/2022
1	lipoprotein cholesterolIBA 01/2022
1	Dihydrotachysterol (AT 10)IBA 01/2022
1	FibrinIBA 01/2022
1	LipidsIBA 01/2022
1	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2021
1	Neprilysin (Neutral Endopeptidase)IBA 01/2021
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2021
1	4- chloro- 3',6'- dimethyl- 2,2'- iminodibenzoate (TO 115)IBA 12/2020
1	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2020
1	CorticosteroneIBA 01/2020
1	Cortodoxone (11 Deoxycortisol)IBA 01/2020
1	GlucocorticoidsIBA 01/2020
1	Epinephrine (Adrenaline)FDA LinkGeneric 01/2019

Therapy/Procedure

15	Therapeutics 04/2024 - 12/2005
8	Denervation 01/2021 - 10/2011
6	Catheters 01/2021 - 01/2011
5	Adrenalectomy 10/2020 - 05/2014
4	Drug Therapy (Chemotherapy) 11/2022 - 12/2006
4	Sympathectomy (Sympathectomies) 01/2021 - 01/2011
2	Radiotherapy 01/2013 - 12/2006
1	Length of Stay 01/2023
1	Bariatric Surgery 01/2022
1	Stem Cell Transplantation 01/2021
1	Renal Dialysis (Hemodialysis) 01/2021